On October 12, 2023, the European Commission (EC) ordered Illumina to unwind its already completed acquisition of the cancer test provider GRAIL Inc. This is the first time that the EC has ordered a reversal of an acquisition. This decision opens a new chapter in the ongoing Illumina/GRAIL saga, which has been unfolding for well…